Pages that link to "Q35561038"
Jump to navigation
Jump to search
The following pages link to Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. (Q35561038):
Displaying 50 items.
- Genetic heterogeneity in autosomal recessive dyskeratosis congenita with one subtype due to mutations in the telomerase-associated protein NOP10 (Q24597936) (← links)
- Flow cytometric immunobead assay for fast and easy detection of PML-RARA fusion proteins for the diagnosis of acute promyelocytic leukemia (Q24604850) (← links)
- Monitoring minimal residual disease in acute myeloid leukaemia: a review of the current evolving strategies (Q26770394) (← links)
- Risk factors for relapse after allogeneic transplantation in acute myeloid leukemia (Q26771438) (← links)
- Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies (Q26828511) (← links)
- Prognostic significance and treatment implications of minimal residual disease studies in Philadelphia-negative adult acute lymphoblastic leukemia (Q27006773) (← links)
- Advancing the Minimal Residual Disease Concept in Acute Myeloid Leukemia (Q28087291) (← links)
- Modulation of cell cycle by graded expression of MLL-AF4 fusion oncoprotein (Q28247462) (← links)
- Imatinib treatment induces CD5 B lymphocytes and IgM natural antibodies with anti-leukemic reactivity in patients with chronic myelogenous leukemia (Q28477798) (← links)
- Dynamics of resistance development to imatinib under increasing selection pressure: a combination of mathematical models and in vitro data (Q28478542) (← links)
- NPM1 deletion is associated with gross chromosomal rearrangements in leukemia (Q28749228) (← links)
- Measurable residual disease testing in acute myeloid leukaemia. (Q30234914) (← links)
- Efficacy and pharmacologic data of second-generation tyrosine kinase inhibitor nilotinib in BCR-ABL-positive leukemia patients with central nervous system relapse after allogeneic stem cell transplantation (Q30836557) (← links)
- Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program. (Q31012437) (← links)
- An 11p15 Imprinting Centre Region 2 Deletion in a Family with Beckwith Wiedemann Syndrome Provides Insights into Imprinting Control at CDKN1C (Q31044124) (← links)
- Comparison of the latest commercial short and long oligonucleotide microarray technologies (Q33236641) (← links)
- Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells. (Q33285468) (← links)
- EVI1 activation in blast crisis CML due to juxtaposition to the rare 17q22 partner region as part of a 4-way variant translocation t(9;22). (Q33350395) (← links)
- Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged second remissions in patients over the age of 55 years with acute myeloid leukemia in late first relapse (Q33412354) (← links)
- Genetic tests to evaluate prognosis and predict therapeutic response in acute myeloid leukemia (Q33555627) (← links)
- Clinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: results of the ALFA-0701 trial (Q33572303) (← links)
- Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial (Q33587563) (← links)
- Hypoxia inducible factor 1alpha gene (HIF-1alpha) splice variants: potential prognostic biomarkers in breast cancer. (Q33630831) (← links)
- Clinical features and prognostic implications of TCF3-PBX1 and ETV6-RUNX1 in adult acute lymphoblastic leukemia (Q33632230) (← links)
- Quantitative assessment of Wilms tumor 1 expression by real-time quantitative polymerase chain reaction in patients with acute myeloblastic leukemia (Q33660751) (← links)
- Latent membrane protein 1 regulates STAT1 through NF-kappaB-dependent interferon secretion in Epstein-Barr virus-immortalized B cells (Q33724152) (← links)
- RNA quantification using gold nanoprobes - application to cancer diagnostics (Q33748792) (← links)
- A sequential approach with imatinib, chemotherapy and transplant for adult Ph acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study. (Q33822032) (← links)
- Long FLT3 internal tandem duplications and reduced PML-RARα expression at diagnosis characterize a high-risk subgroup of acute promyelocytic leukemia patients (Q33829079) (← links)
- Early reduction of WT1 transcripts during induction chemotherapy predicts for longer disease free and overall survival in acute myeloid leukemia (Q33829117) (← links)
- Low numbers of pre-leukemic fusion genes are frequently present in umbilical cord blood without affecting DNA damage response (Q33829330) (← links)
- Cysteine and glycine-rich protein 2 (CSRP2) transcript levels correlate with leukemia relapse and leukemia-free survival in adults with B-cell acute lymphoblastic leukemia and normal cytogenetics (Q33829373) (← links)
- Development of standardized approaches to reporting of minimal residual disease data using a reporting software package designed within the European LeukemiaNet. (Q33873297) (← links)
- High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase chronic myeloid leukemia: first results from the randomized CELSG phase III CML 11 "ISTAHIT" study. (Q33886162) (← links)
- Evaluation of a new flow cytometry based method for detection of BCR-ABL1 fusion protein in chronic myeloid leukemia (Q33889952) (← links)
- Clonal competition in BcrAbl-driven leukemia: how transplantations can accelerate clonal conversion. (Q33908547) (← links)
- Comprehensive characterization of a novel intronic pseudo-exon inserted within an e14/a2 BCR-ABL rearrangement in a patient with chronic myeloid leukemia (Q33947104) (← links)
- Outcomes in patients with relapsed or refractory acute promyelocytic leukemia treated with or without autologous or allogeneic hematopoietic stem cell transplantation (Q33956085) (← links)
- Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia. (Q34022415) (← links)
- The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase (Q34032263) (← links)
- Bone marrow mesenchymal stem cells for improving hematopoietic function: an in vitro and in vivo model. Part 2: Effect on bone marrow microenvironment. (Q34058486) (← links)
- Routine use of microarray-based gene expression profiling to identify patients with low cytogenetic risk acute myeloid leukemia: accurate results can be obtained even with suboptimal samples (Q34144877) (← links)
- Detection of fusion genes at the protein level in leukemia patients via the flow cytometric immunobead assay (Q34152810) (← links)
- Major molecular response achievement in CML Patients can be predicted by BCR-ABL1/ABL1 or BCR-ABL1/GUS ratio at an earlier time point of follow-up than currently recommended (Q34155213) (← links)
- Folylpolyglutamate synthetase gene transcription is regulated by a multiprotein complex that binds the TEL-AML1 fusion in acute lymphoblastic leukemia (Q34161064) (← links)
- A protease-resistant PML-RAR{alpha} has increased leukemogenic potential in a murine model of acute promyelocytic leukemia (Q34310547) (← links)
- Rho GTPase expression in human myeloid cells (Q34390890) (← links)
- Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial (Q34396079) (← links)
- Immunologic minimal residual disease detection in acute lymphoblastic leukemia: A comparative approach to molecular testing (Q34425875) (← links)
- Real-time, fluorescence-based quantitative PCR: a snapshot of current procedures and preferences (Q34433461) (← links)